{
  "docId": "019de070-0ed4-7638-a889-7a7fc1ddc308",
  "docSlug": "5ce7ec09cf381a935cffcd873943f8c1",
  "documentTitle": "Aeglea BioTherapeutics | Results Presentation Deck | 13 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 13,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a timeline-based process diagram to illustrate the study phases.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-0ed4-7638-a889-7a7fc1ddc308/5",
  "deckHref": "/decks/019de070-0ed4-7638-a889-7a7fc1ddc308",
  "deckJsonHref": "/decks/019de070-0ed4-7638-a889-7a7fc1ddc308.json",
  "deckAnchorHref": "/decks/019de070-0ed4-7638-a889-7a7fc1ddc308#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.25,
        "x": 0.73,
        "y": 0.021
      },
      "kind": "callout",
      "text": "Key Objectives: Primary endpoint (Safety/tolerability), Secondary endpoints (Plasma arginine, GC levels), Clinical outcome assessments (6MWT, GMFM), Responder definition.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52bf23b5-8507-4a0b-8603-55c94446c497",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.68,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Study timeline showing 101A and 102A phases, including Part 1, Part 2, and Open-Label Extension.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46f791ec-2277-45c9-a91e-ed9eab747dbd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.03,
        "y": 0.068
      },
      "kind": "list",
      "text": "Inclusion criteria: Diagnosis of ARG1-D, >2 years old. Exclusion criteria: Severe, uncontrolled hyperammonaemia.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b350a24-4490-4b70-ae1b-45bb3741d287",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.46,
        "x": 0.52,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "ARG1-D = Arginase 1 Deficiency; IV = intravenous; QW = weekly; Q2W = every 2 weeks; MCID = Minimal Clinically Important Difference, GMFM = Gross Motor Function Measurement, 6MWT = Six Minute Walk Test",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b46d74d-2848-41ba-9bb4-8f96f20d8955",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.9,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Open-Label, Multi-Centre Phase 1/2 Study of Pegzilarginase in ARG1-D (101A and 102A Studies)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2db90eff-bf5e-4d71-968b-d4888d89662b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "1fdbba0a-dba1-4fdf-8e15-07f15a06bf10",
      "evidence": "The slide uses a horizontal flow to represent the progression of clinical trial phases over time.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 11,
      "from": 5,
      "beatId": "ab1a9bb2-2594-47ca-80cf-39fc8cef5a32",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation showcases Pegzilarginase as a solution",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}